[CAS No.114899-77-3] A936378 Trabectedin 98%
Número de catálogo:
Cas No.:
Fórmula molecular:
Peso molecular:
MDL No:
EINECS:
Pedido/solicitar presupuesto/Soporte técnico
Teléfono: 0086-571-89925085
hacer pedido & consulta: sales@amadischem.com
soporte técnico: tech@amadischem.com
*Todos los productos químicos de nuestra empresa son solo para uso en laboratorio y fabricación.
control de calidad [114899-77-3]

NMR

CNMR

HPLC

LC-MS

documentos relacionados [114899-77-3]
Información básica [114899-77-3]
Sinónimos:
Aspecto:
Punto de fusión:
Punto de ebullición:
Punto de inflamación:
Requisitos de almacenamiento:
Pubchem ID:
Smiles:
Inchi:
InchiKey:
Información de seguridad [114899-77-3]
Pictograma:
Palabra de advertencia:
UN No.:
Categoría de peligro:
Clase de embalaje:
Indicaciones de peligro:
Consejos de prudencia:
Literatura relacionada [114899-77-3]

Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites

Ilaria Craparotta 1,#Laura Mannarino 2,3,#Riccardo Zadro 2,3,#Sara Ballabio 4Sergio Marchini 3Giulio Pavesi 5Marta Russo 6Salvatore Lorenzo Renne 2,7Marina Meroni 1Marianna Ponzo 1Ezia Bello 1Roberta Sanfilippo 8Paolo G Casali 8Maurizio D’Incalci 2,3,Roberta Frapolli 1

  • Author information

  • Article notes

  • Copyright and License information

PMCID: PMC11590625  PMID: 39587691

Abstract

Background

The marine drug trabectedin has shown unusual effectiveness in the treatment of myxoid liposarcoma (MLPS), a liposarcoma characterized by the expression of the FUS-DDIT3 chimera. Trabectedin elicits a significant transcriptional response in MLPS resulting in cellular depletion and reactivation of adipogenesis. However, the role of the chimeric protein in the mechanism of action of the drug is not entirely understood.

Methods

FUS-DDIT3-specific binding sites were assessed through Chromatin Immunoprecipitation Sequencing (ChIP-Seq). Trabectedin-induced effects were studied on pre-established patient-derived xenograft models of MLPS, one sensitive to (ML017) and one resistant against (ML017ET) trabectedin at different time points (24 and 72 h, 15 days). Data were integrated with RNA-Seq from the same models.

Results

Through ChIP-Seq, here we demonstrate that trabectedin inhibits the binding of FUS-DDIT3 to its target genes, restoring adipocyte differentiation in a patient-derived xenograft model of MLPS sensitive to trabectedin. In addition, complementary RNA-Seq data on the same model demonstrates a two-phase effect of trabectedin, characterized by an initial FUS-DDIT3-independent cytotoxicity, followed by a transcriptionally active pro-differentiation phase due to the long-lasting detachment of the chimera from the DNA. Interestingly, in a trabectedin-resistant MLPS model, the effect of trabectedin on FUS-DDIT3 rapidly decreased over time, and prolonged treatment was no longer able to induce any transcription or post-transcriptional modifications.

Conclusions

These findings explain the unusual mechanism underlying trabectedin's effectiveness against MLPS by pinpointing the chimera's role in inducing the differentiation block responsible for MLPS pathogenesis. Additionally, the findings hint at a potential mechanism of resistance acquired in vivo.

Graphical Abstract

graphic file with name 13046_2024_3228_Figa_HTML.jpg

Supplementary Information

The online version contains supplementary material available at 10.1186/s13046-024-03228-z.

Productos similares [114899-77-3]
Detalles del producto [114899-77-3]
Lo sentimos, no hay detalles del producto
precios competitivos
logística eficiente
soporte técnico
stock suficiente